AstraZeneca signs $2bn deal with Chinese firm
Britain’s biggest pharmaceuticals company has agreed a licence agreement with a Chinese company potentially worth up to $2 billion to develop an experimental drug to tackle unhealthy cholesterol levels and related cardiovascular diseases. AstraZeneca has …